SCHEMBL2763141

SCHEMBL2763141

CCCc1ccc(S(=O)(=O)Nc2nc(-c3sccc3Cl)cs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.57
USP2 O75604 1/20 0.57
CYP1A2 P05177 1/20 0.57
POLB P06746 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
MAPT P10636 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
RECQL P46063 1/20 0.57
HSD11B1 P28845 1/20 0.53
KDM1A O60341 7/20 0.51
MAOA P21397 2/20 0.49
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
AKT1 P31749 4/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762498 0.83 KDM1A (0.63) POLBKDM1AMAOAMEN1KMT2A
SCHEMBL5830980 0.82 AKT1 (0.44) AKT1
SCHEMBL5831311 0.81 AKT1 (0.52) MEN1KMT2AAKT1
SCHEMBL2782508 0.81 GAA (0.53) NPSR1KDM1AMAOAMEN1KMT2A
SCHEMBL2762877 0.80 MEN1 (0.72) NPSR1POLBMAPTKDM1AMAOA
SCHEMBL6612760 0.79 FFAR4 (0.47) MAPTMEN1KMT2AAKT1GAA
SCHEMBL2762549 0.79 RORC (0.51) NPSR1KDM1AMAOAMEN1KMT2A
SCHEMBL6615701 0.79 FFAR4 (0.43) CYP3A4MAPTCYP2C19MEN1KMT2A
SCHEMBL2762617 0.77 KDM1A (0.56) POLBMAPTKDM1AMAOAMEN1
SCHEMBL2762583 0.77 POLB (0.67) NPSR1USP2CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
CN-1437588-A 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors BIOVITRUM AB (SE) 2003-08-20 CN claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
CN-1437588-A 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors BIOVITRUM AB (SE) 2003-08-20 CN disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 NPSR1 2986/4885USP2 2823/4885CYP1A2 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.